Effect of Covid-19 on kidney and Liver Functions
الملخص
COVID- 19 affects kidneys and liver, leading to abnormalities in kidney and liver function tests in severe cases. Understanding this interaction is crucial for effective medical care and managing the disease's health implications, with ongoing research and clinical observations. The purpose of this study is to investigate the impact of COVID-19 infections and its link to kidney and liver function impairment by assessing certain enzymes and biochemical indicators in the blood of infected persons. 100 blood samples were collected, 50 from people infected with COVID-19, taken from the COVID-19 Hospital (Burns and Plastic Surgery Hospital/Duhok City and Lalav Hospital/Duhok City) who were diagnosed with the infection according to World Health Organization protocol, and 50-control group were taken from healthy university staff and healthy patient companions who are free of sickness. The results show that patients had significantly higher average in ALP, ALT and AST levels compared to control group, as well as higher average in urea, uric acid, serum creatinine, total serum bilirubin and Cystatin C levels compared to the control group. COVID-19 affects kidneys and liver, leading to abnormalities in kidney and liver function tests in severe cases. Understanding this interaction is crucial for effective medical care and managing the disease's health implications, with ongoing research and clinical observations.
الكلمات المفتاحية:
COVID -19
Creatinine
Uric acid
Hepatotoxicity
Renal toxicity
كيفية الاقتباس
Farah Sameer Salh, Azzam A. Mosa, Rana T. Altaee, & Suhair Mahfoodh Salih. (2024). Effect of Covid-19 on kidney and Liver Functions. مجلة جامعة بني وليد للعلوم الإنسانية والتطبيقية, 9(5), 1-11. https://doi.org/10.58916/jhas.v9i5.536
إصدار
القسم
Article
المراجع
1.
Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM, Ardalan M, Zununi Vahed S. Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms. Reviews in medical virology. 2021 May;31(3): e2176. DOI: 10.1002/rmv.2176.
2.
Al-AAlim AM, Hamad AM and AL-ledani AA. Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects. Iraqi Journal of Veterinary Sciences. 2020 :34(2):287-293.
3.
Ali E, Badawi M, Ahmed A, Abdelmahmuod E and Ibrahim W. Severe SARS‐CoV‐2 infection presenting with acute kidney injury and diabetic ketoacidosis complicated by pancreatitis in a 53‐year man with hypertension. Clinical Case Reports. 2021 Mar;9(3):1202-6. DOI: 10.1002/ccr3.3898.
4.
Almughalles S, Shazaly N, Abdulqadir J and Adham, D. Liver ultrasound evalution of acutely increased liver function tests COVID-19 hospitalized patients. Qatar Medical Journal 2024 Sep; 2024(3). DOI:105339/qmj.2024.46.
5.
Askari H, Sanadgol N, Azarnezhad A, Tajbakhsh A, Rafiei H, Safarpour AR, Gheibihayat SM, Raeis-Abdollahi E, Savardashtaki A, Ghanbariasad A, Omidifar N. Kidney diseases and COVID-19 infections: causes and effect, supportive therapeutics and nutritional perspectives. Heliyon. 2021 Jan 1;7(1). DOI: 10.1016/j.heliyon.2020.e05151.
6.
Bramer LM, Hontz RD, Eisfeld AJ, Sims AC, Kim YM, Stratton KG, Nicora CD, Gritsenko MA, Schepmoes AA, Akasaka O, Koga M. Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections. Heliyon. 2023 Mar 1;9(3). DOI: 10.1016/j.heliyon. 2023.e09956.
7.
Breesam A A and Noraldeen M Y. Study of the immune response of COVID-19 patients in Kirkuk province. Med J Babylon. 2024 Mar; 20; S160-7. DOI: 10.4103/MJBL.MJBL_159_22.
8.
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y. COVID-19: Abnormal liver function tests. Journal of hepatology. 2020 Sep 1;73(3):566-74. DOI: 10.1016/j.jhep.2020.05.040.
9.
Chen S, Yueh MF, Bigo C, Barbier O, Wang K, Karin M, Nguyen N, Tukey RH. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proceedings of the National Academy of Sciences. 2013 Nov 19;110(47):19143-8. DOI: 10.1073/pnas.1314379110.
10.
Crisan D, Avram L, Grapa C, Dragan A, Radulescu D, Crisan S, Grosu A, Militaru V, Buzdugan E, Stoicescu L, Radulescu L. Liver injury and elevated FIB-4 define a high-risk group in patients with COVID-19. Journal of Clinical Medicine. 2021 Dec 28;11(1):153.
11.
Ding P, Song B, Liu X, Fang X, Cai H, Zhang D, Zheng X. Elevated pancreatic enzymes in ICU patients with COVID-19 in Wuhan, China: a retrospective study. Frontiers in Medicine. 2021 Aug 17; 8:663646.
12.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KO, Ahmed Z, Younas S. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of infection and public health. 2020 Dec 1;13(12):1833-9. DOI: 10.1016/j.jiph.2020.09.022.
13.
Gholizadeh P, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K, Esposito S, Khodadadi E, Yousefi M, Samadi Kafil H. Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19). Journal of inflammation research. 2020 Jul 1:285-92.
14.
Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention. Ejmo.2020 Apr;4(2):116-25. DOI: 10.35940/ejmo.4.2.11625.
15.
Huang J, Wang Y, Wang K, Li S, Sun P, Guo Y, Liu J, Yang R, Zeng M, Pan C, Wang H. Biosynthesis and Immunological Evaluation of a Dual-Antigen Nanoconjugate Vaccine against Brucella melitensis. Engineering. 2023 May 12. DOI: 10.1016/j.eng.2023.05.020.
16.
Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. The Journal of clinical investigation. 2010 Jun 1;120(6):1939-49. DOI: 10.1172/JCI41908.
17.
Mohammed SA, Tawfeeq,AA, Noraldin MY. Role of glutathione reduction in causation severe complications of coronavirus disease. Med J Babylon 2019. Mar.20: S149-53.DOI: 10.4103/MJBL.MJBL_178_ 22.
18.
Morais AH, Passos TS, Maciel BL, da Silva-Maia JK. Can probiotics and diet promote beneficial immune modulation and purine control in coronavirus infection? Nutrients. 2020 Jun 10;12(6):1737. DOI: 10.3390/nu12061737.
19.
Nicosia RF, Ligresti G, Caporarello N, Akilesh S, Ribatti D. COVID-19 vasculopathy: mounting evidence for an indirect mechanism of endothelial injury. The American Journal of Pathology. 2021 Aug 1;191(8):1374-84. DOI: 10.1016/j.ajpath.2021.05.033.
20.
Østergaard L. SARS CoV‐2 related microvascular damage and symptoms during and after COVID‐19: Consequences of capillary transit‐time changes, tissue hypoxia and inflammation. Physiological reports. 2021 Feb;9(3):e14726. DOI: 10.14814/phy2.14726.
21.
Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021 May 1;15(3):869-75. DOI: 10.1016/j.dsmcg.2021.03.015
22.
Saba L, Gerosa C, Fanni D, Marongiu F, LA NASA G, Caocci G, Barcellona D, Balestrieri A, Ferdinando C, Orru G, Pierpaolo C. Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review. European Review for Medical and Pharmacological Sciences. 2020;24(23):12609-22. DOI: 10.26355/eurrev_202012_24547.
23.
Sami U, Zahra N, Brijesh S, Krishnaprasad N, Thajus A, Mohaiadeen A, Moustafa O, Mohammed N, Fatima Al and Rafat S.Rehabilitation and functional outcomes of COVID- 19 patients in a rehabilitation hospital in Qatar.Qater Medical Journal.2024 Sep 2024(3):45.DOI: 10.5339/qmj.2024.45.
24.
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. Journal of clinical medicine. 2020 May 11;9(5):1417. DOI: 10.3390/jcm9051417.
25.
Sarkesh A, Sorkhabi AD, Sheykhsaran E, Alinezhad F, Mohammadzadeh N, Hemmat N, Baghi HB. Extrapulmonary clinical manifestations in COVID-19 patients. The American journal of tropical medicine and hygiene. 2020 Nov;103(5):1783. DOI: 10.4269/ajtmh.20-0949.
26.
Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic features of COVID-19: A concise review. Pathology-Research and Practice. 2020 Sep 1;216(9):1530.
27.
Tulu TW, Wan TK, Chan CL, Wu CH, Woo PY, Tseng CZ, Vodencarevic A, Menni C, Chan KH. Machine learning-based prediction of COVID-19 mortality using immunological and metabolic biomarkers. BMC Digital Health. 2023 Feb 3;1(1):6. DOI: 10.1186/s43024-023-0012-7
28.
Vairetti M, Di Pasqua LG, Cagna M, Richelmi P, Ferrigno A, Berardo C. Changes in glutathione content in liver diseases: an update. Antioxidants. 2021 Feb 28;10(3):364. DOI: 10.3390/antiox10030364.
29.
Vinayagam S& Sattu K. SARS-CoV-2 and coagulation disorders in different organs. Life sciences. 2020 Nov 1;260:118431. DOI: 10.1016/j.lfs.2020.118431
30.
Wadman, M., Couzin-Frankel, J., Kaiser, J. and Matacic, C., 2020. A rampage through the body. Science, 368(6490), pp.640-645.
31.
Wang C, Yu C, Novakovic VA, Xie R, Shi J. Circulating microparticles in the pathogenesis and early anticoagulation of thrombosis in COVID-19 with kidney injury. Frontiers in Cell and Developmental Biology. 2022 Jan 18;9:784505. DOI: 10.3389/fcell.2022.7845.
32.
Wang L, Li X, Chen H, Yan S, Li D, Li Y, Gong Z. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. American journal of nephrology. 2020 May 14;51(5):343-8. DOI: 10.1159/000506713.
33.
Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020 Oct 1;73(4):807-16. DOI: 10.1016/j.jhep.2020.06.008.
34.
Wang Y, Sheng G, Shi L, Cheng X. Increased serum total bilirubin-albumin ratio was associated with bilirubin encephalopathy in neonates. Bioscience Reports. 2020 Jan;40(1): BSR20192152. DOI: 10.1042/BSR20192152.
35.
Weiss C, Carriere M, Fusco L, Capua I, Regla-Nava JA, Pasquali M, Scott JA, Vitale F, Unal MA, Mattevi C, Bedognetti D. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS nano. 2020 Jun 10;14(6):6383-406. DOI: 10.1021/acsnano.0c04942.
36.
World Health Organization. Getting your workplace ready for COVID-19: how COVID-19 spreads, 19 March 2020. World Health Organization; 2020.
37.
Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver international. 2020 Jun;40(6):1321-6.
38.
Zaki N, Alashwal H& Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020 Sep 1;14(5):1133-42. DOI: 10.1016/j.dsmcg.2020.07.009
39.
Zhang LY, Huang LS, Yue YH, Fawaz R, Lim JK, Fan JG. Acute hepatitis of unknown origin in children: Early observations from the 2022 outbreak. Journal of clinical and translational hepatology. 2022 Jun 6;10(3):522. DOI: 10.14218/JCTH.2022.0320
